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Abstract
Background: Atropine sulfate is an anticholinergic agent for treatment of hypertrophic pyloric stenosis and is orally
administrated as a triturate with lactose hydrate. Because of the low safety margin of atropine sulfate, triturate
uniformity is a key safety factor. In this study, we assessed the uniformity of atropine sulfate in 1000-fold triturates
prepared by wet mixing and dry mixing methods and discussed the cause of the difference in uniformity between two
preparation methods.
Methods: A 1000-fold triturate of atropine sulfate with lactose hydrate was prepared by two different methods: wet
mixing and dry mixing. The wet mixing was performed according to Kurashiki Central Hospital protocol and the dry
mixing was a simple physical mixing by a rocking mixer. The uniformity of atropine sulfate content in aliquots of a
1000-fold triturate with lactate hydrate was assessed by liquid chromatography–tandem mass spectrometry (LC–MS/
MS) quantification. Solid-state analyses of the triturates by Raman chemical imaging and X-ray powder diffraction
(XRPD) were performed to investigate the difference in uniformity.
Results: The LC–MS/MS quantification showed that the uniformity of atropine sulfate in the 1000-fold triturate
was excellent for wet mixing but was significantly variable for dry mixing. On the basis of the Raman chemical
imaging and XRPD analyses, it was indicated that an amorphous thin film of atropine sulfate coated the surfaces
of the lactose hydrate particles during wet mixing and contributed to the uniformity of the triturate. In contrast,
clusters of the crystalline atropine sulfate were found in the dry mixing samples.
Conclusion: The results showed that better atropine sulfate triturate uniformity was achieved using the wet
mixing method rather than the dry method and the cause of the uniformity difference between two mixing
methods was indicated by the multilateral assessment.
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Background
Atropine sulfate is an anticholinergic alkaloid that has
been used to prevent muscarinic effects of anticholines-
terases in adults [1]. It has also been used in an oral dos-
age form for treatment of infant hypertrophic pyloric
stenosis [2]. The dose of atropine sulfate is 0.2–0.5 mg
per administration for adults and decreases to approxi-
mately 0.05 mg per kg body weight for infants. Because
atropine is a nonselective anticholinergic agent and toxic
effects often appear even at therapeutic doses, careful
administration of atropine sulfate is required.
In Kurashiki Central Hospital, a 1000-fold triturate of
pure atropine sulfate with lactose hydrate is prepared for
administration, with the aim of improving handling in
weighing and dosing and decreasing errors in the divided
weight. However, because of the large particle size of the
crystalline atropine sulfate, it is believed that simple dry
mixing with lactose hydrate causes poor uniformity of
atropine sulfate in the triturate, and consequently, wide
variation in the amount of drug that is actually dosed.
To overcome this problem, some institutions including
Kurashiki Central Hospital prepare the triturate using a
wet mixing method: the crystalline atropine sulfate is
dissolved in water followed by mixing of the solution
with lactose hydrate and drying.
The uniformity of an active pharmaceutical ingredient
(API) in the triturate is undoubtedly a key factor in the
safety of low-dose formulations with low safety margins,
such as that for atropine sulfate. Although the uniform-
ity of the triturate generally has been assessed by liquid-
phase quantification of the API in an aliquot of triturate,
solid-phase chemical imaging techniques such as Raman
chemical imaging can provide more detail and direct in-
formation on the uniformity of the triturate because the
particle size and dispersion state of the API can easily be
shown by the imaging [3–8].
In this study, we compared the uniformity of the API
in a 1000-fold triturate of atropine sulfate with lactose
hydrate prepared by two different methods: wet mixing
and dry mixing, using liquid chromatography–tandem
mass spectrometry (LC–MS/MS) quantification of atro-
pine sulfate [9]. To investigate the differences in the
solid-state properties, such as the crystallinity and dis-
persion, we analyzed the triturates using Raman chem-
ical imaging and X-ray powder diffraction (XRPD).
Methods
Preparation of triturate of atropine sulfate I: Wet mixing
method
10-fold triturate was prepared as follows. A 1.0 g amount
of atropine sulfate (Pfizer Japan Inc., Tokyo, Japan) was
dissolved in 1 mL of water. To the solution, 9.0 g of lactose
hydrate was added and mixed. The mixture was then dried
at 60 °C for 5 h and sieved on 80 mesh. 100-fold triturate
was prepared similarly and 1000-fold triturate was ob-
tained by diluting 100-fold triturate with lactose hydrate.
Preparation of triturate of atropine sulfate II: Dry mixing
method
10-fold triturate was prepared as follows. To 1.0 g of
atropine sulfate, 9.0 g of lactose hydrate was added,
and the whole powder was mixed using RM-10 rock-
ing mixer (Aichi Electric Co., Ltd., Aichi, Japan) for
30 min. The rotation and rocking speeds were 75 rpm
and 10 rpm, respectively. 100-fold triturate was pre-
pared similarly and 1000-fold triturate was obtained
by diluting 100-fold triturate with lactose hydrate.
LC–MS/MS quantification
A 250 mg aliquot of the 1000-fold atropine sulfate tritur-
ate was dissolved and diluted to obtain a 50.0 ng/mL at-
ropine sulfate aqueous solution. The HPLC system of
LC–MS/MS was an Agilent 1100 series (Agilent, Santa
Clara, CA, USA) with an analytical column (CAPCELL
PAK C18 MGIII S-5, 100 mm × 2.0 mm i.d., SHISEIDO,
Tokyo, Japan). The isocratic mobile phase consisted of a
40:60 (v/v) mixture of 0.1 % (v/v) formic acid and aceto-
nitrile. The flow rate of the mobile phase was 0.3 mL/
min. Mass spectrometric detection was performed on a
PE Sciex API 2000 spectrometer equipped with an APCI
source (AB Sciex, Toronto, Canada).
Raman and XRPD analyses
Raman chemical imaging for triturates of atropine sul-
fate was performed on an inVia Raman microscope
system (Renishaw Plc., Gloucestershire, UK) under a
785 nm excitation laser. Powder sample was spread
evenly on a glass plate, and Raman chemical image
was recorded (10 mm × 10 mm area, 42.5 μm spatial
resolution). Discrimination of atropine sulfate and lac-
tose hydrate was performed according to direct clas-
sical least squares modelling [10]. The XRPD patterns
were acquired on a Rigaku MultiFlex diffractometer
(Rigaku Corporation, Tokyo, Japan). The 2θ range was
5°–70° at a 0.02° pitch.
Results and Discussion
The content of atropine sulfate in a 250 mg portion of the
1000-fold triturate was measured by LC–MS/MS. Figure 1
shows the variation in the detected concentrations of
atropine sulfate in the triturates from each preparation
method. The 15 samples from the wet mixing method
showed very small variations in the 50.0 ng/mL concentra-
tions of atropine sulfate (mean ± SD, 53.7 ± 1.7 ng/mL).
The 15 samples from the dry mixing method showed a
high degree of variability that ranged from 16.0 ng/mL to
243 ng/mL (51.6 ± 55.9 ng/mL), although the mean was
close to the calculated value. The sample variance of the
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dry mixing method was significantly greater than that of
the wet mixing method (F-test, α < 0.01). This result indi-
cated that the 1000-fold triturate of atropine sulfate pre-
pared by the wet mixing method was very uniform;
whereas, dry mixing caused wide variation in the API con-
tent of the triturate. Considering the safety of the low-dose
atropine sulfate triturate preparation with a low safety
margin, the results indicated that the wet mixing method
would be preferred over a simple physical dry mixing
method to minimize the chance of overdosing, which in-
curs systemic adverse reactions such as tachycardia, blood
pressure elevation, restlessness, irritability, and delirium.
Next, to understand the dispersion of chemicals in
solid samples, we applied Raman chemical imaging to
triturates prepared by two methods. Interestingly, atro-
pine sulfate was rarely detected by Raman chemical im-
aging in a 10 mm× 10 mm area of triturates prepared by
the wet mixing method (Fig. 2a–c). On the other hand,
the triturates prepared by the dry mixing method showed
obvious clusters of atropine sulfate (Fig. 2d–f ). The large
variance in API content in the 250 mg aliquot of the
1000-fold triturate can be easily explained by the existence
of clusters of atropine sulfate. However, the question of
why the Raman signal of atropine sulfate disappeared in
the wet mixing samples needs to be explained. We hy-
pothesized that the crystalline atropine sulfate was trans-
formed to the amorphous state during the wet mixing
procedure and thoroughly coated the surface of the lac-
tose hydrate particles as a thin film. Amorphous atropine
sulfate exhibited a much lower Raman signal intensity
than the crystalline form (Fig. 3); therefore, it was sup-
posed that the peaks in the spectrum of the thin film of
Fig. 1 Variations in atropine sulfate concentrations in aliquots of the
1000-fold triturate prepared by two methods. Solid circles and bars
indicate the individual concentrations of atropine sulfate detected
by liquid chromatography–tandem mass spectrometry and the
mean value, respectively, for each preparation method
Fig. 2 Raman chemical imaging of 10-, 100-, and 1000-fold triturates prepared by the wet or dry mixing method (10 mm× 10 mm, 42.5 μm spatial
resolution). Panels a, b, and c represent the image of 10-, 100-, and 1000-fold triturates by the wet mixing, respectively. Panels d, e, and f represent the
image of 10-, 100-, and 1000-fold triturates by the dry mixing, respectively. Red and green areas indicate atropine sulfate and lactose hydrate, respectively
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the amorphous atropine sulfate on lactose hydrate would
be hidden by the much stronger intensities of the Raman
peaks of the underlying lactose hydrate.
To prove this, we performed XRPD to assess the crys-
tallinity of atropine sulfate in the triturates. Crystalline
atropine sulfate exhibited a distinctive diffraction signal
at 15.5° (Fig. 4a). In the 10-fold triturate, the signal of
the crystalline atropine sulfate was much stronger in the
dry mixing than in the wet mixing (Fig. 4b). This means
that the amorphous atropine sulfate, which showed no
striking diffraction signal in XRPD, was the majority in
the wet mixing samples. The same tendency was found
Fig. 3 Raman spectra of the crystalline and amorphous forms of atropine sulfate
Fig. 4 X-ray powder diffraction (XRPD) patterns of the standard sample and triturates. a XRPD patterns of the crystalline atropine sulfate and
lactose hydrate. Red arrow indicates the distinctive diffraction signal of the crystalline atropine sulfate. b–d XRPD patterns of the 10-, 100-, and
1000-fold triturates prepared by the wet or dry mixing methods
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in the 100-fold triturate (Fig. 4c), although no signal of
atropine sulfate was detected in the 1000-fold triturates be-
cause the content of atropine sulfate was too low (Fig. 4d).
The XRPD results strongly support the hypothesis that
amorphous atropine sulfate resulted from the wet mixing
method.
Conclusions
In this study, we found that much higher uniformity of
atropine sulfate in the triturate was achieved using the
wet mixing preparation method of Kurashiki Central
Hospital than using the dry mixing method. Solid-state
analyses by Raman chemical imaging and XRPD indi-
cated that in the triturate prepared by wet mixing, the
atropine sulfate transformed into the amorphous form
and coated the surfaces of the particles of the excipient.
On the other hand, the dry mixing preparation method
caused biased dispersion of atropine sulfate, with large
clusters of crystalline drug particles. The solid-state ana-
lytical findings consistently explained why wet mixing
preparation of the triturate resulted in higher uniformity
of the API. These analyses can provide evidence or hints
regarding the cause of uniformity and can contribute to
development of better triturate preparation methods in
pharmacy for low-dose and low safety margin drugs and
to safer medications.
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